{"filing":{"accession_number":"0001193125-26-269358","cik":"0001840233","ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"xlo-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526269358/xlo-20260610.htm"},"events":[{"id":10781,"run_id":9459,"accession_number":"0001193125-26-269358","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Xilio Therapeutics held its Annual Meeting of stockholders on June 10, 2026, with voting results on the election of four Class II directors (Bello, Curran, Ross, and Xu), ratification of Ernst \u0026 Young LLP as independent auditor, and approval of amendments to the 2021 Stock Incentive Plan regarding prefunded warrant shares.","company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","filing_date":"2026-06-12","submitted_at":null,"items":[{"id":7180,"accession_number":"0001193125-26-269358","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 filing discloses the results of the June 10, 2026 Annual Meeting of stockholders, including election of four Class II directors (Bello, Curran, Ross, and Xu), ratification of Ernst \u0026 Young LLP as independent auditor, and approval of amendments to the 2021 equity plan regarding prefunded warrant shares. The disclosure presents voting tallies for each matter, which is the core content of shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:17:19.809763+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10782,"run_id":9459,"accession_number":"0001193125-26-269358","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.72,"summary":"Stockholders approved an amendment and restatement of the 2021 Stock Incentive Plan, which affects equity grants and awards across the company. A director reclassification (Curran's transition from Class II to Class III) was also disclosed but is administrative in nature.","company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","filing_date":"2026-06-12","submitted_at":null,"items":[{"id":7179,"accession_number":"0001193125-26-269358","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"While the section discloses both a director reclassification (Curran's resignation as Class II and re-appointment as Class III) and stockholder approval of an amended stock incentive plan, the material substance centers on the stockholder-approved amendment and restatement of the 2021 Stock Incentive Plan. The director reclassification is administrative (no compensation changes, same person, same board), whereas the plan amendment is a compensatory arrangement affecting equity grants and awards across the company. The explicit reference to stockholder approval and incorporation of the full plan description signals materiality of the compensation plan change.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:17:19.809763+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7179,"accession_number":"0001193125-26-269358","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"While the section discloses both a director reclassification (Curran's resignation as Class II and re-appointment as Class III) and stockholder approval of an amended stock incentive plan, the material substance centers on the stockholder-approved amendment and restatement of the 2021 Stock Incentive Plan. The director reclassification is administrative (no compensation changes, same person, same board), whereas the plan amendment is a compensatory arrangement affecting equity grants and awards across the company. The explicit reference to stockholder approval and incorporation of the full plan description signals materiality of the compensation plan change.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:17:19.809763+00:00","company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","filing_date":"2026-06-12"},{"id":7180,"accession_number":"0001193125-26-269358","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 filing discloses the results of the June 10, 2026 Annual Meeting of stockholders, including election of four Class II directors (Bello, Curran, Ross, and Xu), ratification of Ernst \u0026 Young LLP as independent auditor, and approval of amendments to the 2021 equity plan regarding prefunded warrant shares. The disclosure presents voting tallies for each matter, which is the core content of shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:17:19.809763+00:00","company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","filing_date":"2026-06-12"}]}